DOP2010000152A - Compuestos de 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para la produccion de los mismos, una composicion farmaceutica y una combinacion que los comprende. - Google Patents

Compuestos de 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para la produccion de los mismos, una composicion farmaceutica y una combinacion que los comprende.

Info

Publication number
DOP2010000152A
DOP2010000152A DO2010000152A DO2010000152A DOP2010000152A DO P2010000152 A DOP2010000152 A DO P2010000152A DO 2010000152 A DO2010000152 A DO 2010000152A DO 2010000152 A DO2010000152 A DO 2010000152A DO P2010000152 A DOP2010000152 A DO P2010000152A
Authority
DO
Dominican Republic
Prior art keywords
compounds
production
arilpropil
hidroxi
onas
Prior art date
Application number
DO2010000152A
Other languages
English (en)
Inventor
Markus Berger
Hartmut Rehwinkel
Thomas Zollner
Ekkehard May
Jorma Hassfeld
Original Assignee
Astrazeneca Ab
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39575536&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2010000152(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Bayer Schering Pharma Ag filed Critical Astrazeneca Ab
Publication of DOP2010000152A publication Critical patent/DOP2010000152A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/56—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds
    • C07C45/57—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom
    • C07C45/58—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom in three-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/32—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by aldehydo- or ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

la presente invencion se refiere a compuestos de formula I, donde los substituyentes R1, R2, R3, R4 Y R5 poseen los significados definidos en las reivindicaciones. La invencion tambien se refiere a un proceso para la produccion de dichos compuestos, a composiciones farmaceuticas y a combinaciones que los comprenden.
DO2010000152A 2007-11-22 2010-05-21 Compuestos de 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para la produccion de los mismos, una composicion farmaceutica y una combinacion que los comprende. DOP2010000152A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07076019A EP2062880A1 (en) 2007-11-22 2007-11-22 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents

Publications (1)

Publication Number Publication Date
DOP2010000152A true DOP2010000152A (es) 2010-08-15

Family

ID=39575536

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2010000152A DOP2010000152A (es) 2007-11-22 2010-05-21 Compuestos de 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para la produccion de los mismos, una composicion farmaceutica y una combinacion que los comprende.

Country Status (40)

Country Link
US (3) US8394958B2 (es)
EP (2) EP2062880A1 (es)
JP (1) JP5559058B2 (es)
KR (1) KR101580700B1 (es)
CN (2) CN103396300A (es)
AR (1) AR069400A1 (es)
AU (1) AU2008328307C1 (es)
BR (1) BRPI0819833B1 (es)
CA (1) CA2705410C (es)
CL (1) CL2008003472A1 (es)
CO (1) CO6280419A2 (es)
CR (1) CR11452A (es)
CU (1) CU23889B1 (es)
CY (1) CY1118173T1 (es)
DK (1) DK2234979T3 (es)
DO (1) DOP2010000152A (es)
EA (1) EA017459B1 (es)
EC (1) ECSP10010192A (es)
ES (1) ES2588170T3 (es)
HK (1) HK1144817A1 (es)
HN (1) HN2010001060A (es)
HR (1) HRP20161015T1 (es)
HU (1) HUE028865T2 (es)
IL (1) IL205117A (es)
LT (1) LT2234979T (es)
MA (1) MA31834B1 (es)
MX (1) MX2010005528A (es)
MY (1) MY151017A (es)
NZ (1) NZ585495A (es)
PA (1) PA8804601A1 (es)
PE (1) PE20091066A1 (es)
PL (1) PL2234979T3 (es)
PT (1) PT2234979T (es)
RS (1) RS55012B1 (es)
SI (1) SI2234979T1 (es)
TN (1) TN2010000219A1 (es)
TW (1) TWI520736B (es)
UA (1) UA100251C2 (es)
UY (1) UY31479A1 (es)
WO (1) WO2009065503A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1878717A1 (en) 2006-07-14 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Benzyl amines, a process for their production and their use as anti-inflammatory agents
WO2009151569A2 (en) * 2008-06-09 2009-12-17 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
US20100016338A1 (en) * 2008-07-21 2010-01-21 Bayer Schering Pharma Aktiengesellschaft 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1-arylquinolin-2-ones, a Process for their Production and their Use as Anti-inflammatory Agents
JP6061373B2 (ja) * 2012-07-24 2017-01-18 国立研究開発法人産業技術総合研究所 ２−ヒドロキシベンズアルデヒド化合物、これを含有するコラーゲン細胞外分泌阻害剤及び医薬品組成物
WO2017025371A1 (en) * 2015-08-07 2017-02-16 Bayer Pharma Aktiengesellschaft Process for the preparation of 5-amino-quinolin-2(1h)-ones and their tautomer forms 5-amino-quinolin-2-ols
US20190008867A1 (en) 2015-11-13 2019-01-10 Ph Pharma Co., Ltd. 4-(4-cyano-2-thioaryl)dihydropyrimidinones for treating chronic wounds
WO2017161518A1 (en) 2016-03-23 2017-09-28 Astrazeneca Ab New physical form
WO2018046684A1 (en) 2016-09-08 2018-03-15 Bayer Pharma Aktiengesellschaft Process for the preparation of substituted 5-{[2-(alkoxymethyl)-3,3,3-trifluoro-2-hydroxy-1-phenylpropyl]amino}quinolin-2(1h)-ones
WO2018046685A1 (en) 2016-09-08 2018-03-15 Bayer Aktiengesellschaft Quinoline derivatives for treatment of inflammatory skin diseases
WO2018046678A1 (de) 2016-09-08 2018-03-15 Bayer Aktiengesellschaft Glukokorticoid-rezeptor-agonisten enthaltende formulierungen
WO2018046681A1 (en) 2016-09-08 2018-03-15 Bayer Pharma Aktiengesellschaft Forms of 5-{[(1s,2s)-1-(2-chloro-3-fluoro-4-methoxyphenyl)-3,3,3-trifluoro-2-hydroxy-2-(methoxymethyl)propyl]amino}-7-fluoro-1h-quinolin-2-one
CA3123490A1 (en) * 2019-01-22 2020-07-30 Akribes Biomedical Gmbh Selective glucocorticoid receptor modifiers for treating impaired skin wound healing

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1045180A (en) 1963-09-20 1966-10-12 Parke Davis & Co Quinazoline derivatives
US4197209A (en) * 1977-03-10 1980-04-08 Ciba-Geigy Corporation Lubricant compositions containing sulfur-containing esters of phosphoric acid
JPH06172321A (ja) 1992-10-08 1994-06-21 Agro Kanesho Co Ltd 置換アミノピリミジン誘導体、その製造法及びそれを有効成分とする有害生物駆除剤
UA57002C2 (uk) * 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
WO2000010977A1 (en) 1998-08-21 2000-03-02 The Scripps Research Institute Catalytic asymmetric aminohydroxylation with amino-substituted heterocycles
DE10038639A1 (de) 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
CN1310912C (zh) 2000-12-22 2007-04-18 史密丝克莱恩比彻姆有限公司 5－[4－[2－(n－甲基－n－(2－吡啶基)氨基)乙氧基]苄基]噻唑烷－2,4－二酮甲磺酸盐
CA2477764A1 (en) * 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US20050090559A1 (en) * 2003-07-01 2005-04-28 Markus Berger Heterocyclically-substituted pentanol derivatives, process for their production and their use as anti-inflammatory agents
MXPA06000169A (es) 2003-07-01 2006-04-27 Schering Ag Derivados de pentanol heterociclicamente sustituidos, procedimiento para su preparacion y su uso como anti-inflamatorios.
US20050009109A1 (en) * 2003-07-08 2005-01-13 Stanford University Fluorophore compounds and their use in biological systems
DE10347385A1 (de) * 2003-10-08 2005-05-12 Schering Ag Umgelagerte Pentanole, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
EP1878717A1 (en) * 2006-07-14 2008-01-16 Bayer Schering Pharma Aktiengesellschaft Benzyl amines, a process for their production and their use as anti-inflammatory agents
US20100016338A1 (en) * 2008-07-21 2010-01-21 Bayer Schering Pharma Aktiengesellschaft 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1-arylquinolin-2-ones, a Process for their Production and their Use as Anti-inflammatory Agents

Also Published As

Publication number Publication date
ECSP10010192A (es) 2010-07-30
HUE028865T2 (en) 2017-01-30
CN103396300A (zh) 2013-11-20
HRP20161015T1 (hr) 2016-11-18
CO6280419A2 (es) 2011-05-20
UA100251C2 (uk) 2012-12-10
PL2234979T3 (pl) 2016-11-30
CU20100099A7 (es) 2011-10-14
USRE47047E1 (en) 2018-09-18
EP2062880A1 (en) 2009-05-27
PA8804601A1 (es) 2009-06-23
US20130005766A1 (en) 2013-01-03
TW200927112A (en) 2009-07-01
CY1118173T1 (el) 2017-06-28
CA2705410C (en) 2016-04-12
UY31479A1 (es) 2009-07-17
WO2009065503A1 (en) 2009-05-28
LT2234979T (lt) 2016-11-10
ES2588170T3 (es) 2016-10-31
TN2010000219A1 (en) 2011-11-11
JP5559058B2 (ja) 2014-07-23
AU2008328307C1 (en) 2013-10-24
HK1144817A1 (es) 2011-03-11
CN101868448A (zh) 2010-10-20
IL205117A (en) 2015-05-31
AR069400A1 (es) 2010-01-20
RS55012B1 (sr) 2016-11-30
IL205117A0 (en) 2010-11-30
MY151017A (en) 2014-03-31
AU2008328307B2 (en) 2013-03-28
JP2011504472A (ja) 2011-02-10
BRPI0819833A2 (pt) 2015-05-26
EP2234979B1 (en) 2016-05-25
CR11452A (es) 2010-07-15
HN2010001060A (es) 2012-11-12
US20090137564A1 (en) 2009-05-28
EA017459B1 (ru) 2012-12-28
KR20100092936A (ko) 2010-08-23
NZ585495A (en) 2011-05-27
PE20091066A1 (es) 2009-08-27
EA201000814A1 (ru) 2010-12-30
CL2008003472A1 (es) 2009-11-20
AU2008328307A1 (en) 2009-05-28
KR101580700B1 (ko) 2015-12-28
CN101868448B (zh) 2013-06-12
BRPI0819833B1 (pt) 2018-11-27
MA31834B1 (fr) 2010-11-01
EP2234979A1 (en) 2010-10-06
PT2234979T (pt) 2016-08-29
CA2705410A1 (en) 2009-05-28
US8394958B2 (en) 2013-03-12
US8680117B2 (en) 2014-03-25
MX2010005528A (es) 2010-06-02
SI2234979T1 (sl) 2016-12-30
TWI520736B (zh) 2016-02-11
DK2234979T3 (en) 2016-09-05
CU23889B1 (es) 2013-04-19

Similar Documents

Publication Publication Date Title
DOP2010000152A (es) Compuestos de 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para la produccion de los mismos, una composicion farmaceutica y una combinacion que los comprende.
UY31524A1 (es) Nuevos compuestos 010
UY31046A1 (es) Derivados sustituidos de n-(3,4-dihidro-2h-cromen-3-il)formamida y n-(1, 2,3 ,4-tetrahidronaftalen-2-il)formamida, sales de los mismos, composiciones que los contienen, procedimientos para su preparacion y aplicaciones
UY31260A1 (es) Compuestos de pirazol, composiciones conteniendolos y aplicaciones.
BR122019010008B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
CL2012001391A1 (es) Compuestos derivados de triazolopiridina sustituidos, inhibidores de la quinasa mps-1; composición farmacéutica; procedimiento de preparacion; combinación farmacéutica y uso para la profilaxis o tratamiento de una enfermedad hiperproliferativa tal como tumores hematológicos, sólidos y/o sus metástasis; compuestos intermediarios.
CR20140275A (es) Triazolopiridinas sustituidas
UY28747A1 (es) Nuevo proceso para la sintesis y nueva forma cristalina de agomelatina y composiciones farmaceuticas que las contienen
UY29886A1 (es) Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones
ATE547415T1 (de) Inhibitoren der wechselwirkung zwischen mdm2 und p53
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
GT200600144AA (es) 1h-quinazolin-2,4-dionas (solicitud fraccionaria, derivada de la solicitud de patente de invencion pi-2006-00144)
ATE431333T1 (de) Amino-propanolderivate
AR055314A1 (es) Un derivado de isoxazolina que tiene una parte hemicetal de acido carboxilico ciclico para usar como un inhibidor de caspasa, un procedimiento para prepararlo, una composicion farmaceutica que lo comprende y uso del mismo
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
EA200901124A1 (ru) Соединения формулы (i) в качестве ингибиторов серинпротеазы
AR062211A1 (es) Derivados de 6-carboxi-normorfinano. composiciones farmaceuticas
ATE496044T1 (de) Indolylmaleimidderivate
UY29325A1 (es) Nuevos derivados de 2 - amino-piridina
ECSP088229A (es) Derivados de pirazolona como inhibidores de 11-beta hsd1
GT200800285A (es) Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmaceuticas que las comprenden
BRPI0817223B8 (pt) inibidores da interação entre mdm2 e p53, seu processo de preparação e seu uso, composição farmacêutica que os compreende e combinação
PA8855001A1 (es) Monocarbamas
UA106880C2 (uk) Нові гербіциди
RS51661B (en) NEW DIOSMETHINE DERIVATIVES, THE PROCEDURE FOR THEIR MAKING AND THE PHARMACEUTICAL MIXTURES CONTAINING THEM